COVID-19 UPDATE

BDSI remains committed to the chronic pain community during the COVID-19 pandemic. For more
information on access to our products, please call our customer service line at 1-800-469-0261.

Analyst Coverage

Analyst Coverage

Analyst
Firm
Brandon Folkes
Cantor Fitzgerald
Oren Livnat
HC Wainwright & Co.
Tim Chiang
Northland Securities
David Amsellem
Piper Sandler
Scott Henry
ROTH Capital Partners
Gregg Gilbert
SunTrust Robinson Humphrey, Inc.
Tim Lugo
William Blair

BioDelivery Sciences International, Inc. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding BioDelivery Sciences International, Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of BioDelivery Sciences International, Inc. or its management. BioDelivery Sciences International, Inc. does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.

Investor Presentation

More information is coming soon.


Recent BDSI News

BioDelivery Sciences Reports First Quarter 2021 Results May 6, 2021

Total Company Net Revenue of $41 Million , an Increase of 7% versus Prior Year Net Income of $5.2 Million , EBITDA Margin of 22% and Operating Cash Generation of $11 Million Conference Call and Webcast Scheduled for 8:30 AM EST Today RALEIGH, N.C. , May 06, 2021 (GLOBE NEWSWIRE) -- BioDelivery ...

Read more
BioDelivery Sciences to Report First Quarter 2021 Financial Results on May 6, 2021 April 20, 2021

RALEIGH, N.C. , April 20, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that it will report its first quarter 2021 ...

Read more
BioDelivery Sciences Reports Strong Q4 and Record Full-Year 2020 Results March 10, 2021

Total Company Net Revenue Increased 40% versus Prior Year to Reach an All-Time High of $156.5 Million Record Level Profitability with Net Income of $25.7 Million , Full-Year EBITDA Margin of 26% and Operating Cash Generation of $25 Million Conference Call and Webcast Scheduled for 8:30 AM EST Today ...

Read more

Upcoming Events

More events are coming soon.

Stay Connected

Stay up to date on the latest news

Get started now
June 7, 2021 /
Data provided by West LLC. Minimum 15 minutes delayed.